Pablo G. Legorreta - 15 Jun 2020 Form 3/A - Amendment Insider Report for Royalty Pharma plc (RPRX)

Role
CEO, Chairman of the Board, Director
Signature
/s/ Jason Mehar, as Attorney-in-Fact, for Pablo G. Legorreta
Issuer symbol
RPRX
Transactions as of
15 Jun 2020
Net transactions value
$0
Form type
3/A - Amendment
Filing time
15 Apr 2022, 18:45:00 UTC
Date Of Original Report
15 Jun 2020
Next filing
15 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RPRX LP interests in RPI US Partners 2019, LP 15 Jun 2020 Class A Ordinary Shares, par value $0.0001 per share 1,584,810 $0.000000 By Spouse F1, F2
holding RPRX LP interests in RPI US Partners 2019, LP 15 Jun 2020 Class A Ordinary Shares, par value $0.0001 per share 8,802,380 $0.000000 By Legorreta Investments LLC F1, F3
holding RPRX ICAI Interests 15 Jun 2020 LP interests in RPI US Partners 2019, LP 1,719,074 $0.000000 By Legorreta Investments LLC F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share, par value $0.0001 per share ("Class A Ordinary Share") of the Issuer for no additional value.
F2 These RPI US LP Interests held by the Reporting Person's Spouse were omitted from the Reporting Person's original Form 3 filing due to an inadvertent administrative error.
F3 This amendment to Form 3 is being filed to correct the terms and the number of RPI US LP Interests and ICAI Interests that was incorrectly reported on the Reporting Person's original Form 3 due to an inadvertent administrative error.
F4 These ICAI Interests represent a grant of up to 1,719,074 RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share.